Current Oncology Reports

, Volume 15, Issue 2, pp 98–104

Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer

Evolving Therapies (RM Bukowski, Section Editor)

DOI: 10.1007/s11912-012-0284-2

Cite this article as:
Tang, P.A. & Heng, D.Y.C. Curr Oncol Rep (2013) 15: 98. doi:10.1007/s11912-012-0284-2

Abstract

Programmed death 1 (PD-1) is a T cell co-inhibitory receptor with two ligands, PD-L1 and PD-L2. In cancer, this pathway plays a major role in immune resistance in the tumor environment. Blockade of this pathway can enhance antitumor immune responses. This review discusses the preclinical rationale for PD-1 pathway inhibition in advanced renal cell carcinoma and prostate cancer, in addition to the clinical activity and toxicity of the anti-PD-L1 antibody BMS-936559, as well as anti-PD-1 antibodies MK-3475 and BMS-936558.

Keywords

Renal cell carcinoma Prostate cancer Programmed death 1 

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Tom Baker Cancer CenterUniversity of CalgaryCalgaryCanada

Personalised recommendations